Considering the need of new therapies for NAFLD and the crosstalk between insulin signaling, WAT and the liver, we aimed to identify specific effects of Peptide 2 diet supplementation on manifestations of the metabolic syndrome including systemic IR, WAT response to insulin and NAFLD markers, compared with the thiazolidinedione rosiglitazone. The gene discussed is INS; the disease is metabolic syndrome.